Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.

Targeting KRAS in cancer

Open access
Singhal, Anupriya, Li, Bob T., O’Reilly, Eileen M.·2024·Nature Medicine

Abstract

RAS family variants—most of which involve KRAS—are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites. But recent developments in bioengineering, organic chemistry and related fields have provided the infrastructure to make direct KRAS targeting possible. The first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents—sotorasib and adagrasib. Inhibitors targeting other variants beyond G12C have shown preliminary antitumor activity in highly refractory malignancies such as pancreatic cancer. Herein, we outline RAS pathobiology with a focus on KRAS, illustrate therapeutic approaches across a variety of malignancies, including emphasis on the ‘on’ and ‘off’ switch allele-specific and ‘pan’ RAS inhibitors, and review immunotherapeutic and other key combination RAS targeting strategies. We summarize mechanistic understanding of de novo and acquired resistance, review combination approaches, emerging technologies and drug development paradigms and outline a blueprint for the future of KRAS therapeutics with anticipated profound clinical impact. Recent developments in bioengineering and organic chemistry have enabled targeting of the previously ‘undruggable’ KRAS; this review summarizes the successes, challenges and future of KRAS therapeutics in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02903-0

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 127 references

Cited by

See all 332

Metadata

Authors
Singhal, A., Li, B. T., & O’Reilly, E. M.
Venue
Nature Medicine
Published
2024-04
Volume
30
Issue
4
Pages
969-983
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4394931737
Cited by
332
References
127
FWCI
38.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting KRAS in cancer. https://app.cochat.ai/papers/10.1038/s41591-024-02903-0
The paper
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024). Targeting KRAS in cancer. Nature Medicine. https://doi.org/10.1038/s41591-024-02903-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.